Acalculous pyelonephritis and cholecystitis occurring simultaneously in a diabetic patient on sitagliptin therapy

Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is th...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmacology & pharmacotherapeutics Vol. 6; no. 3; pp. 172 - 174
Main Authors Sahoo, Jayaprakash, Kamalanathan, Sadishkumar, Vivekanandan, Muthupillai, Swaminathan, Rathinam Palamalai
Format Journal Article
LanguageEnglish
Published India Medknow Publications and Media Pvt. Ltd 01.07.2015
Sage Publications Ltd
Medknow Publications & Media Pvt Ltd
Subjects
Abdomen
Case Report
Case studies
Cholecystitis
Diabetes
Diabetes therapy
Dosage and administration
Gallbladder diseases
Health aspects
Hypoglycemia
Infections
Insulin
Postmenopausal women
Pyelonephritis
Signal transduction
Sitagliptin
Studies
Tumor necrosis factor-TNF
Urinary tract diseases
Urine
Urogenital system
Women
India
infection
oral hypoglycemic agents
Dipeptidyl peptidase-4
Online AccessGet full text

Cover

More Information
Summary:Dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of anti-diabetic drugs. They control both fasting and postprandial hyperglycemia by inhibiting degradation of incretin hormones, such as, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Sitagliptin is the first DPP-4 inhibitor to be marketed in India. In addition to its glucose lowering effect, it also suppresses immunity resulting in various infections in a diabetes patient. Here, we describe the simultaneous development of two infections (acalculous pyelonephritis and cholecystitis) in a postmenopausal female patient, well-controlled on sitagliptin-based anti-diabetic therapy.
ISSN:0976-500X
0976-5018
DOI:10.4103/0976-500X.162016